ABTA: Raising Awareness, Providing Support & Funding Research

In this episode of “Moving Medicine Forward” – The Podcast, Lily McNally and Heidi Shenk from the American Brain Tumor Association (ABTA) share their personal connections to brain tumors and discuss the ABTA’s resources, research initiatives, and community partnerships. They also discuss ABTA’s “Meet Hope Head On” campaign to triple research funding and expand patient outreach. Tune in to learn how the ABTA is advancing brain tumor research and how you can get involved or donate: CTI Cares Employee Fund  

0:23 Meet our guests from the American Brain Tumor Association (ABTA), Lily McNally and Heidi Shenk, who share their personal stories and connection to the organization. 

0:52 Heidi discusses her personal experience with brain tumors and how it led her to become involved with the ABTA. 

3:11 Lily shares her journey and how her family's experience with brain tumors inspired her to contribute to the mission of the ABTA. 

4:33 Heidi and Lily talk about how their families became involved with the ABTA and its supportive community. 

7:21 Learn about the various resources the ABTA offers to patients and families, and how these services have personally benefited Heidi and Lily. For help, call the ABTA Care Line: 800-886-ABTA(2282). 

11:36 Heidi and Lily explain ABTA’s partnerships with marathons, including Cincinnati’s Flying Pig, and how local events support their mission. 

13:47 Discover how physicians, alumni, and others can contribute to the ABTA’s efforts, including its annual national conference. [Learn more about the Alumni Research Network (AARN): ABTA Alumni Research Network - Learn More or Donate Today!]  

15:43 The ABTA’s 5-year campaign, Meet Hope Head On, aims to triple research funding, double patient outreach, and increase federal funding for oncology research. [Link to donate: CTI Cares Employee Fund]  

17:15 Discover how the ABTA partners with clinical research organizations like CTI to help patients access clinical trials and advance treatment options. [Link to Clinical Trial Finder: Home | ClinicalTrials.gov] 

19:45 In August 2024, the FDA approved a new treatment for low-grade glioblastomas. [Get the latest information on this treatment: VORANIGO® (vorasidenib) | For Grade 2 IDH-Mutant Glioma]